Skip to content
Datasets/TCGA-GBM

Glioblastoma Multiforme

MixedProject-curated
TCGAAvailable from GDC and IDC

617 glioblastomas with twelve measurement types including radiology on 607 and pathology slides on 389 - the reference glioma cohort, with a median follow-up of 12.0 months.

Can it answer your research question?

5 of 6 supported
  • Overall survival

    Supported

    Vital status and time are populated; median follow-up 1.0 years; 596 cases with follow-up; endpoints: overall survival, progression-free interval.API

  • Progression or recurrence

    Supported

    A time to event is derivable: progression-free interval; progression_or_recurrence is informative for 63% of cases.API

  • Treatment response

    Supported

    disease_response is populated for 88% of cases; criteria: complete response, progressive disease.API

  • Which drug was given

    Supported

    therapeutic_agents is recorded for 72% of cases.API

  • Stage-adjusted modelling

    Not supported

    ajcc_pathologic_stage is informative for no case in the harmonized records.API

  • Analysis by race or ethnicity

    Supported

    Race is informative for 93% of cases.API

Judged from the repository’s own field completeness (thresholds). “Not measured” means we have not probed that field for this record, not that the data lack it.

At a glance

Every percentage is the repository’s own record of what is filled in
CasesAPI2
617
Measurement types
12
30,587 files, 239 TB
Follow-upAPI
12.0 months
for 596 of 617 cases; overall survival, progression-free interval
Treatment responseAPI
Recorded
complete response, progressive disease, stable disease

SubjectCALC

Brain and central nervous system

As filed by the repository

GliomasNot ReportedBrain

Who is in the cohortAPI

A usable value“Not reported” or “unknown”No value recorded
  • Sex366 male · 230 female · 4 unknown · 17 no value recorded
  • Race507 white · 51 black or african american · 13 asian · 29 not reported · 17 no value recorded
  • Ethnicity490 not hispanic or latino · 13 hispanic or latino · 97 not reported · 17 no value recorded
  • Vital status492 dead · 102 alive · 6 not reported · 17 no value recorded

Age at diagnosis

Median 60, middle half 50–69, range 11–89 years across 596 cases.

What was measured, and on how many

12 measurement types, 1 covering the whole cohort.

  • Clinical617 of 617 · 100%
  • DICOM medical imaging607 of 617 · 98%
  • SNP genotyping array (copy number, germline)599 of 617 · 97%
  • DNA methylation array423 of 617 · 69%
  • Whole exome sequencing401 of 617 · 65%
  • Whole-slide diagnostic images389 of 617 · 63%
  • Whole genome sequencing347 of 617 · 56%
  • Somatic Structural Variation335 of 617 · 54%
  • Bulk RNA sequencing293 of 617 · 47%
  • microRNA sequencing273 of 617 · 44%
  • Reverse phase protein array237 of 617 · 38%
  • ATAC sequencing (chromatin accessibility)9 of 617 · 1%
Platform, files and data levels
AssayPlatformFilesLevels
ClinicalAPI2-1,219-
DICOM medical imagingAPI--DICOM series
SNP genotyping array (copy number, germline)APIillumina7,348-
DNA methylation arrayAPIillumina1,350-
Whole exome sequencingAPIillumina7,897-
Whole-slide diagnostic imagesAPI2illumina860-
Whole genome sequencingAPI2illumina4,688-
Somatic Structural VariationAPI-1,089-
Bulk RNA sequencingAPIillumina3,519-
microRNA sequencingAPIillumina834-
Reverse phase protein arrayAPIillumina243-
ATAC sequencing (chromatin accessibility)APIillumina9-
How complete all 29 clinical fields are - 12 informative for at least 80% of cases

A field counts as informative only when it holds a real value. “Not reported” blocks an analysis just as a missing field does. Fields marked 1:n can hold several records per case, so they show the share of cases with any record.

Informative - a usable valuePresent but uninformative - “not reported” or “unknown”Absent - no value recorded

Outcome

  • Vital statusAPI96%
  • Cause of deathAPI0%
  • Progression or recurrenceAPI0%
  • Last known disease statusAPI0%

Follow-up

  • Disease response at follow-upAPI86%
  • Progression at follow-upAPI63%
  • ECOG performance statusAPI12%

Treatment

  • Prior treatment1:nAPI97%
  • Treatment type1:nAPI94%
  • Treatment given1:nAPI94%
  • Therapeutic agents1:nAPI72%
  • Treatment outcomeAPI11%
  • Regimen or line of therapyAPI0%

Staging

  • AJCC pathologic stageAPI0%
  • AJCC clinical stageAPI0%

Diagnosis

  • Primary diagnosis1:nAPI97%
  • Tissue or organ of origin1:nAPI97%
  • Prior malignancyAPI8%
  • Synchronous malignancyAPI5%

Pathology

  • Morphology (ICD-O)1:nAPI97%
  • Classification of tumor1:nAPI97%
  • Tumor gradeAPI0%

Demographics

  • Sex at birthAPI97%
  • RaceAPI93%
  • EthnicityAPI82%
  • Country of residenceAPI3%
  • Population groupAPI0%

Exposure

  • Tobacco smoking statusAPI0%
  • Alcohol historyAPI0%

Access

MixedSome components are open; others need approval.API

Data Access Request through dbGaP using an eRA Commons account; institutional signing official approval required

Open components
13,117 open-access files
Controlled components
17,470 controlled-access files
Typical turnaround
days to a few weeks after signing official approval
License
NIH Genomic Data Sharing Policy terms
Citation requirement
Cite the dataset accession and the program's publication guidelines; see the GDC publication policy.

What it is good for

Written and checked by a reviewer, not generated from metadata.

  1. 1. Do imaging features add prognostic or subtype information beyond molecular data in glioblastoma?

    Needs another datasetn ≈ 389HUMAN

    Radiology on 607 cases and pathology slides on 389, paired with expression on 293, methylation on 423 and copy number on 599 for the same patients. Glioma is the disease where imaging is most clinically central, and this pairing is openly available.

    Statistical note: The intersection of imaging and expression is well below 617; build it explicitly. Imaging is in a separate repository from the molecular data.

    NeedsRadiology imagingHistopathology slidesBulk RNA sequencingDNA methylation
  2. 2. Does a new glioma classifier reproduce established methylation subgroups?

    Answerable as shippedn ≈ 423HUMAN

    Methylation on 423 cases with subgroup definitions established across a large literature makes this the standard validation set for glioma classification.

    Statistical note: Extensive prior use means good performance here is weak evidence of generalization.

    NeedsDNA methylationBulk RNA sequencing
  3. 3. Which molecular features associate with survival in glioblastoma?

    Answerable as shippedn ≈ 594HUMAN

    Vital status is informative for 96.3% of 617 cases, giving a clean overall survival endpoint on a well-characterized cohort.

    Statistical note: Follow-up time is recorded across three different GDC fields and is null in the most obvious one; derive it from days to death, follow-up records and diagnosis records together, and state your derivation.

    NeedsBulk RNA sequencingDNA methylationClinical dataOutcome data

What it cannot tell you

1 blocking

Written by a reviewer against the source, not inferred from what is missing.

BlockingMissing dataHUMAN

Progression or recurrence is populated for 0.6% of cases and informative for none, so progression-free survival cannot be derived at all.

Affects: Progression-free survival; Recurrence biology

Mitigation: Restrict to overall survival, derived from vital status and days to death.

MajorTreatment contextHUMAN

Treatment type is recorded for 94% and therapeutic agents for 72%, but the cohort spans an era in which standard therapy changed, and treatment is unrandomised.

Affects: Treatment-response claims; Predictive biomarkers

Mitigation: Adjust for enrolment era; frame findings as associative.

MajorStatistical powerHUMAN

Molecular coverage is uneven - expression 293, exome 401, ATAC 9 - so multi-omic analyses run on much less than 617 cases.

Affects: Multi-omic integration

Mitigation: Build the intersection first; note that ATAC covers 9 cases only.

MinorPlatform obsolescenceHUMAN

Methylation and copy number rely on platforms no longer in routine use.

Affects: Integration with contemporary cohorts

Mitigation: Restrict to shared features.

MajorPopulation coverageHUMAN

507 of 617 patients are recorded as white and 51 as Black or African American.

Affects: Disparities research

Mitigation: Limited power for race-stratified analysis.

Not appropriate for

  • Progression-free survival analysis. - Progression is informative for no case in the record.HUMAN
  • Claiming a classifier generalizes from TCGA-GBM performance alone. - The cohort has been used extensively for method development.HUMAN

Who has used it

Articles that analyzed these data, counted separately from articles that only cited the paper. Only the first counts as reuse.

Analyzed the dataCALC2
1,399
accession in the methods; 100% of a 29-article sample really cited it
Declared using it
174
named in a data availability statement
Cited the paper
6,091
attention to the publication, not reuse of the data
Against expectation
As expected or above
about 538 articles expected; index 1.38

What articles did with it

Only the last row counts as reuse. Where the accession appears in an article tells us what the authors did with the data.

  • Cited the paper6,091
  • Mentioned the dataset272
  • Accession found in text0
  • Declared using it174
  • Analyzed the data1,399

Against comparable datasets

1,399 articles analyzed these data. About 538 would be expected. The expectation comes from a model of size, age, breadth and access tier.

  • Analyzed it1,399
  • Expected~538
Reuse assessment
  • Reuse is within the expected range for comparable datasets (index +1.38).

Compared against 132 datasets in this corpus with a citable accession and sufficient metadata. See Methods for the model.

Articles that analyzed the data

Examples, not the full list. 112 articles matching this dataset's accession search were retrieved and graded individually; these are the strongest of those.

Deep-review sample: author overlap and funding were checked only for the 10 articles listed here, not for every article examined. Of the 10 that analyzed the data, 10 of the 10 we could check had no author in common with the generating team, and 2 of the 9 we could check were themselves NCI-funded. These are sample counts, not population estimates.

Community examples

Share your example

Analyses someone ran on these data end to end, each with a receipt recording when it ran, against which packages and for how long.

advanced

Which cohorts have both imaging and molecular data on the same patients, and how many patients actually carry both?

Join the same patients across two NCI repositories

CD2S workbooks · ran 21 Sept 2026
pythonabout two minutesexecuted
Required inputs
  • Open GDC and IDC APIs, no account required
  • pandas
Expected outputs
  • Patient-level intersection between a GDC project and an IDC collection
  • Counts of molecular-only, imaging-only and joined patients
  • A map of every cohort present in both repositories
  • A chart comparing molecular and imaging patient counts per linkable cohort
Steps
  1. Retrieve patient identifiers from the GDC project
  2. Query IDC's public SQL endpoint for the collection's patient identifiers
  3. Intersect on the shared barcode and quantify the overlap
  4. Sweep every GDC project against every IDC collection

Start here

Starter code generated from this record’s own identifiers, then the access steps.

Get the data in code

GDC: list open files and download thempython

Open-access files need no account. Controlled files need an approved dbGaP request and a token passed to gdc-client.

import json, requests

PROJECT = "TCGA-GBM"
filters = {"op": "and", "content": [
    {"op": "in", "content": {"field": "cases.project.project_id", "value": [PROJECT]}},
    {"op": "in", "content": {"field": "access", "value": ["open"]}},
]}
params = {"filters": json.dumps(filters),
          "fields": "file_id,file_name,data_category,data_type,file_size",
          "size": "10000", "format": "JSON"}
files = requests.get("https://api.gdc.cancer.gov/files", params=params, timeout=60).json()["data"]["hits"]
print(len(files), "open files")

# Write a manifest and fetch with the GDC client (https://gdc.cancer.gov/access-data/gdc-data-transfer-tool)
with open("manifest.txt", "w") as fh:
    fh.write("id\n" + "\n".join(f["file_id"] for f in files))
# $ gdc-client download -m manifest.txt
GDC: clinical table for every casepython
import json, requests

filters = {"op": "in", "content": {"field": "project.project_id", "value": ["TCGA-GBM"]}}
params = {"filters": json.dumps(filters), "size": "5000", "format": "TSV",
          "fields": ",".join([
              "submitter_id", "demographic.vital_status", "demographic.days_to_death",
              "diagnoses.days_to_last_follow_up", "diagnoses.ajcc_pathologic_stage",
              "diagnoses.treatments.treatment_type", "diagnoses.treatments.treatment_outcome"])}
tsv = requests.get("https://api.gdc.cancer.gov/cases", params=params, timeout=60).text
open("TCGA-GBM_clinical.tsv", "w").write(tsv)
IDC: pull the DICOM collection with idc-indexpython

pip install idc-index. Images are public; the package uses s5cmd under the hood.

from idc_index import IDCClient

COLLECTION = "tcga_gbm"
client = IDCClient()

series = client.index[client.index["collection_id"] == COLLECTION]   # one row per DICOM series
print(len(series), "series,", series["PatientID"].nunique(), "patients,",
      round(series["series_size_MB"].sum() / 1024, 1), "GB")
print(series["Modality"].value_counts().to_dict())

# Everything above is an index lookup and costs nothing. Uncomment to pull the pixels;
# the client refuses up front if the disk cannot hold them.
# client.download_from_selection(collection_id=COLLECTION, downloadDir="./tcga_gbm")
This page as data: limitations firstbash
curl -s https://cd2s.vercel.app/data/datasets/gdc-tcga-gbm.json | python3 -c '
import json, sys
r = json.load(sys.stdin)
for l in r["limitations"]:
    print(l["severity"].upper(), "-", l["statement"][:120])
print("survival endpoint:", r["longitudinal"]["has_survival_endpoint"], "| treatment response:", r["longitudinal"]["has_treatment_response"])'

Access steps

  1. 1
    Download open derived molecular files from the GDCFor people1 hour
    https://portal.gdc.cancer.gov/projects/TCGA-GBM
  2. 2
    Add imaging from the Imaging Data CommonsFor people1-2 hours

    Openly available for the same patients, and the cohort's most under-used asset.

    https://portal.imaging.datacommons.cancer.gov/explore/?collection_id=tcga_gbm
  3. 3
    Request controlled access only for sequence-level workFor peopledays to a few weeks

    Requires: eRA Commons account, institutional signing official approval

    https://gdc.cancer.gov/access-data/obtaining-access-controlled-data
  4. 4
    Query the project from code, with no credentialsFor agents

    The file index is public even where files are not, so an agent can size the cohort before anyone requests access.

    curl -s 'https://api.gdc.cancer.gov/files' --get \
      --data-urlencode 'filters={"op":"in","content":{"field":"cases.project.project_id","value":["TCGA-GBM"]}}' \
      --data-urlencode 'fields=file_id,file_name,data_type' \
      --data-urlencode 'size=10000' --data-urlencode 'format=TSV'
    https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/

    Generated from repository policy. Check the linked policy before downloading.

  5. 5
    Pass the token when the agent needs controlled filesFor agents

    Without a token, an API query may return only the open subset. Compare returned counts with the record before treating them as the whole cohort.

    Requires: GDC authentication token

    curl -H "X-Auth-Token: $GDC_TOKEN" https://api.gdc.cancer.gov/data/<file_id>
    https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/

    Generated from repository policy. Check the linked policy before downloading.

Provenance

All of it, and more, is in this record’s JSON.

Identifiers

Versions and verification

Released
1 Jan 2009
Metadata retrieved
18 Sept 2026
Review status
Project-curatedCD2S project curation on 18 Sept 2026
Data generation funding
Funded data generation
Open questions from review
  • The machine-inferred primary publication for this record is a TCGA GBM analysis rather than the cohort's marker paper. Replace with the correct marker citation on next review.

Funding

Awards resolved through NIH RePORTER. Awards that paid to generate these data are listed apart from awards that paid to reuse them. Both are returns on NCI investment, but different ones.

Funded data generation

  • U24CA144025Harvard Genome Characterization CenterRaju S. KucherlapatiFY2009-2016API
  • U24CA143848Gene Expression Patterns in Human Tumors Identified Using Transcript SequencingDavid N Hayes, CHARLES M PEROUFY2009-2016API
  • U24CA126563HudsonAlpha Cancer Genome Characterization CenterRichard M MyersFY2006-2009API
  • U24CA126561Cancer Genome Characterization Center at Johns HopkinsSTEPHEN B. BAYLINFY2006-2009API
  • U24CA126554Cancer Genomics CenterRaju S. KucherlapatiFY2006-2009API
  • U24CA126551The Berkeley Cancer Genome CenterJOE W. GRAYFY2006-2009API
  • U24CA126546Center for Cancer Genome CharacterizationMatthew L. MeyersonFY2006-2009API
  • U24CA126544Cancer Genome Characterization using Gene Expression and DNA Copy Number AnalysisCHARLES M PEROUFY2006-2009API
  • U24CA126543The TCGA Cancer Genome Characterization Center at MSKCCMarc LadanyiFY2006-2009API
  • R01CA099041Genomic & Genetic Characterization of Amplicons in GBMsLYNDA CHINFY2003-2007API

Funded reuse of these data

  • R01CA260271Multi-scale modeling of glioma for the prediction of treatment response, treatment monitoring and treatment allocationOlivier GevaertFY2021-2025API

Funded infrastructure or harmonization

  • P30CA091842Tissue Procurement CoreMark A. Watson, EDUARDO ROSA-MOLINARFY2001-2026API

For softwarerecord JSON